tiprankstipranks
Nurix Therapeutics $125M Spot Secondary; price range $14.50-$15.50
PremiumThe FlyNurix Therapeutics $125M Spot Secondary; price range $14.50-$15.50
9d ago
Nurix Therapeutics Announces Proposed Public Offering
PremiumPress Releases
Nurix Therapeutics Announces Proposed Public Offering
9d ago
Nurix Therapeutics announces $125M common stock offering
PremiumThe Fly
Nurix Therapeutics announces $125M common stock offering
9d ago
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
PremiumPress ReleasesNurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
11d ago
Nurix Therapeutics reports Q1 EPS (76c), consensus (80c)
PremiumThe Fly
Nurix Therapeutics reports Q1 EPS (76c), consensus (80c)
11d ago
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
PremiumPress Releases
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
11d ago
Nurix Therapeutics announces extension of collaboration with Gilead
PremiumThe FlyNurix Therapeutics announces extension of collaboration with Gilead
19d ago
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
PremiumPress Releases
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
19d ago
Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees
PremiumThe Fly
Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees
27d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100